Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review

Iwan Harries; Kate Liang; Matthew Williams; Bostjan Berlot; Giovanni Biglino; Patrizio Lancellotti; Juan Carlos Plana; Chiara Bucciarelli-Ducci

doi:10.1016/j.jaccao.2020.04.011

Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review

JACC CardioOncol. 2020 Jun 16;2(2):270-292. doi: 10.1016/j.jaccao.2020.04.011. eCollection 2020 Jun.

Authors

Iwan Harries¹, Kate Liang¹, Matthew Williams¹, Bostjan Berlot^{1

2}, Giovanni Biglino^{1

3}, Patrizio Lancellotti^{4

5}, Juan Carlos Plana⁶, Chiara Bucciarelli-Ducci¹

Affiliations

¹ Bristol Heart Institute, Bristol National Institute of Health Research (NIHR) Biomedical Research Centre, University Hospitals Bristol NHS Trust and University of Bristol. Bristol, United Kingdom.
² Department of Cardiology, University Medical Centre Ljubljana, Slovenia.
³ National Heart and Lung Institute, Imperial College London, London, United Kingdom.
⁴ University of Liège Hospital, GIGA Cardiovascular Sciences, Departments of Cardiology, Heart Valve Clinic, CHU Sart Tilman, Liège, Belgium.
⁵ Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy.
⁶ Texas Heart Institute at Baylor St. Luke's Medical Center, Baylor College of Medicine, Houston, Texas, USA.

Abstract

This paper aims to empower and inform cardio-oncologists by providing a practical guide to the clinical application of cardiac magnetic resonance (CMR) in the rapidly evolving field of cardio-oncology. Specifically, we describe how CMR can be used to assess the cardiovascular effects of cancer therapy. The CMR literature, relevant societal guidelines, indication-specific imaging protocols, and methods to overcome some of the challenges encountered in performing and accessing CMR are reviewed.

Keywords: CMR, cardiac magnetic resonance; ECV, extracellular volume fraction; EGE, early gadolinium enhancement; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac event; SSFP, balanced steady state free precession; cardio-oncology; cardiotoxicity; cardiovascular magnetic resonance; chemotherapy; left ventricular dysfunction; tissue characterization.

Publication types

Review